Eupraxia Pharmaceuticals (EPRX) Other Operating Expenses (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Other Operating Expenses of -$1.9 million for Q1 2026, down 180333.49% year-over-year from N/an in Q1 2025, and down 180333.49% quarter-over-quarter from -$1075.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Other Operating Expenses (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Other Operating Expenses for 4 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 180333.49% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 521.98% YoY), while the FY2024 annual figure was $18611.0, up 484.05% from the prior year.
- Other Operating Expenses slipped to -$1.9 million in Q1 2026 per EPRX's latest filing, from -$1075.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $2.1 million in Q4 2023 and bottomed at -$3.7 million in Q2 2023.
- Historically, Other Operating Expenses has averaged -$64907.8 across 4 years, with a median of $2150.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Operating Expenses soared 345.17% — and 2026, when it plunged 180333.49%.
- Eupraxia Pharmaceuticals' Other Operating Expenses stood at $2.1 million in 2023, then tumbled by 98.56% to $29979.0 in 2024, then plunged by 103.59% to -$1075.0 in 2025, then plunged by 180333.49% to -$1.9 million in 2026.
- Business Quant data shows EPRX's Other Operating Expenses at -$1.9 million in Q1 2026, -$1075.0 in Q4 2025, and $2150.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1,075.00 |
| Jun 30, 2025 | 2,150.00 |
| Mar 31, 2025 | -1,075.00 |
| Dec 31, 2024 | 29,979.00 |
| Jun 30, 2024 | 430,499.00 |
| Mar 31, 2024 | 770,042.00 |
| Dec 31, 2023 | 2.08 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -314,080.00 |